The combination of feladilimab and the PD-1 blocking antibody pembrolizumab increased both proinflammatory cytokine production ex vivo (dissociated NSCLC tumors) and antitumor activity in a humanized mouse tumor model (A2058), providing additional rationale to evaluate the combination clinically. This evidence concerns the gene PDCD1 and neoplasm.